Long term response to apalutamide and other updates impacting patients with nmCRPC from ASCO GU 2021

Bookmark and Share
Published: 22 Feb 2021
Views: 2155
Rating:
Save
Prof Axel Merseburger and Prof Matthew Smith

Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) and Prof Mathew Smith (Harvard Medical School, Boston, USA) discuss the long term response to apalutamide and other updates impacting patients with non-metastatic castration resistant prostate cancer (nmCRPC) from ASCO GU 2021.

They initially discuss the long-term efficacy of apalutamide for nmCRPC and then they talk about the other treatment options that are available for such patients. Prof Smith and Merseburger talk about the molecular determinants associated with long-term response to apalutamide (APA) in nmCRPC. They then compare the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC). They also discuss real-world data regarding apalutamide efficacy.

In the end, they discuss what’s next for nmCRPC patients in the future.

This programme has been supported by an unrestricted educational grant from Janssen.